The 7 major genital warts markets reached a value of US$ 813.8 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 1,335.5 Million by 2034, exhibiting a growth rate (CAGR) of 5.66% during 2023-2034.
The genital warts market has been comprehensively analyzed in this report titled "Genital Warts Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Genital warts refer to a sexually transmitted infection caused by a low-risk strain of human papillomavirus. The condition results in the formation of tiny bumps or growths in and around the genitals and rectum. Warts typically appear following one to eight months after exposure. The disease is transmitted through skin-to-skin contact and sexual activities, including vaginal, oral, and anal sex. The common indications associated with genital warts are mild bleeding, discomfort, burning sensation, itching, irritation, etc. This ailment often does not produce significant physical markers, but an outbreak might result in emotional problems like anxiety in some people. The diagnosis typically involves a review of the patient's medical history, underlying symptoms, and physical examination. The healthcare practitioner may also perform an acetowhite test, which helps to make genital warts more visible. Additionally, various diagnostic procedures, such as colposcopy and biopsy, are required to visually examine the cervix, vagina, and vulva in order to confirm a diagnosis.
The increasing prevalence of human papillomavirus infections caused by the non-usage of condoms or dental dams during sex is primarily driving the genital warts market. In addition to this, the rising incidence of several associated risk factors, such as a weakened immune system, multiple sexual partners, engaging in sexual activity at an early age, etc., is also bolstering the market growth. Furthermore, the widespread utilization of topical immunomodulatory agents, including imiquimod and cidofovir, to stimulate the immune system in order to attack the virus that causes the warts is acting as another significant growth-inducing factor. Apart from this, the inflating application of cryosurgery, which utilizes liquid nitrogen to freeze and disrupt warts, is further creating a positive outlook for the market. Moreover, the emerging popularity of loop electrosurgical excision procedures for treating the condition is also propelling the market growth. This method uses a thin, low-voltage, electrically charged wire loop to separate warts from the skin by heating the margin of the affected area. Additionally, the escalating demand for interferon alfa-n3 injection to manage the ailment, since it can be administered directly into the lesion with a quicker onset of action, is expected to drive the genital warts market in the coming years.
This report provides an exhaustive analysis of the genital warts market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for genital warts and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the genital warts market in any manner.
Recent Developments:
In March 2024, Merck announced plans to launch the development of an innovative investigational multivalent human papillomavirus (HPV) vaccine aimed at providing broader protection against various HPV strains. Additionally, the firm plans to perform clinical trials in both males and females to examine the safety and efficacy of a single-dose regimen of GARDASIL 9 (Human Papillomavirus 9-valent, recombinant) compared to the current approved three-dose regimen.
In March 2024, Verrica Pharmaceuticals Inc. announced that its lead medication, YCANTH, has been granted New Chemical Entity (NCE) status and a listing in the Orange Book by the United States FDA, resulting in a minimum of five years of regulatory exclusivity.
In January 2024, Verrica Pharmaceuticals Inc. disclosed that it had received the minutes from the Company's recent Type C meeting with the United States Food and Drug Administration (FDA), which took place on November 6, 2023, to review the Phase 3 clinical development strategy for YCANTH for the treatment of warts.
In June 2023, the Joint Committee on Vaccination and Immunisation (JCVI) advised that teenagers and eligible GBMSM under the age of 25 years will only receive a single HPV vaccination beginning in September 2023.
Key Highlights:
The prevalence of genital HPV infections is estimated to be between 10% and 20%, with clinical symptoms in 1%.
About one out of every 100 sexually active people in the U.S. has genital warts at any given moment.
The worldwide prevalence of HPV infection in women with normal cytology is approximately 11-12%, with the highest incidences in sub-Saharan Africa (24%), Eastern Europe (21%), and Latin America (16%).
The prevalence of HPV is typically high in young adults, reaching a peak between the ages of 25 and 29 years and stabilizing or slightly decreasing thereafter.
Approximately 30% of men above the age of 15 have at least one kind of genital HPV infection.
Drugs:
Aldara (imiquimod) belongs to a class of medicines known as immune response modifiers. It is indicated for the treatment of genital warts - the drug acts by stimulating the immune system to battle aberrant skin growths in patients.
SB 206 is a topical investigational drug by Novan for treating genital warts caused by HPV. This therapeutic candidate releases nitric oxide and has the potential to treat skin diseases. The Phase 2 results of SB206 12% for the treatment of external genital warts showed statistically substantial elimination of baseline warts in individuals suffering from the disease.
Ranpirnase, a ribonuclease (RNase), is a member of the enzyme superfamily that catalyzes RNA degradation and mediates a variety of important biological functions, including cell proliferation, maturation, differentiation, and cell death. It is a potential applicant for facilitating the development of medicines for life-threatening disorders like genital warts.
The genital warts market has been comprehensively analyzed in this report titled "Genital Warts Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Genital warts refer to a sexually transmitted infection caused by a low-risk strain of human papillomavirus. The condition results in the formation of tiny bumps or growths in and around the genitals and rectum. Warts typically appear following one to eight months after exposure. The disease is transmitted through skin-to-skin contact and sexual activities, including vaginal, oral, and anal sex. The common indications associated with genital warts are mild bleeding, discomfort, burning sensation, itching, irritation, etc. This ailment often does not produce significant physical markers, but an outbreak might result in emotional problems like anxiety in some people. The diagnosis typically involves a review of the patient's medical history, underlying symptoms, and physical examination. The healthcare practitioner may also perform an acetowhite test, which helps to make genital warts more visible. Additionally, various diagnostic procedures, such as colposcopy and biopsy, are required to visually examine the cervix, vagina, and vulva in order to confirm a diagnosis.
The increasing prevalence of human papillomavirus infections caused by the non-usage of condoms or dental dams during sex is primarily driving the genital warts market. In addition to this, the rising incidence of several associated risk factors, such as a weakened immune system, multiple sexual partners, engaging in sexual activity at an early age, etc., is also bolstering the market growth. Furthermore, the widespread utilization of topical immunomodulatory agents, including imiquimod and cidofovir, to stimulate the immune system in order to attack the virus that causes the warts is acting as another significant growth-inducing factor. Apart from this, the inflating application of cryosurgery, which utilizes liquid nitrogen to freeze and disrupt warts, is further creating a positive outlook for the market. Moreover, the emerging popularity of loop electrosurgical excision procedures for treating the condition is also propelling the market growth. This method uses a thin, low-voltage, electrically charged wire loop to separate warts from the skin by heating the margin of the affected area. Additionally, the escalating demand for interferon alfa-n3 injection to manage the ailment, since it can be administered directly into the lesion with a quicker onset of action, is expected to drive the genital warts market in the coming years.
This report provides an exhaustive analysis of the genital warts market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for genital warts and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the genital warts market in any manner.
Recent Developments:
In March 2024, Merck announced plans to launch the development of an innovative investigational multivalent human papillomavirus (HPV) vaccine aimed at providing broader protection against various HPV strains. Additionally, the firm plans to perform clinical trials in both males and females to examine the safety and efficacy of a single-dose regimen of GARDASIL 9 (Human Papillomavirus 9-valent, recombinant) compared to the current approved three-dose regimen.
In March 2024, Verrica Pharmaceuticals Inc. announced that its lead medication, YCANTH, has been granted New Chemical Entity (NCE) status and a listing in the Orange Book by the United States FDA, resulting in a minimum of five years of regulatory exclusivity.
In January 2024, Verrica Pharmaceuticals Inc. disclosed that it had received the minutes from the Company's recent Type C meeting with the United States Food and Drug Administration (FDA), which took place on November 6, 2023, to review the Phase 3 clinical development strategy for YCANTH for the treatment of warts.
In June 2023, the Joint Committee on Vaccination and Immunisation (JCVI) advised that teenagers and eligible GBMSM under the age of 25 years will only receive a single HPV vaccination beginning in September 2023.
Key Highlights:
The prevalence of genital HPV infections is estimated to be between 10% and 20%, with clinical symptoms in 1%.
About one out of every 100 sexually active people in the U.S. has genital warts at any given moment.
The worldwide prevalence of HPV infection in women with normal cytology is approximately 11-12%, with the highest incidences in sub-Saharan Africa (24%), Eastern Europe (21%), and Latin America (16%).
The prevalence of HPV is typically high in young adults, reaching a peak between the ages of 25 and 29 years and stabilizing or slightly decreasing thereafter.
Approximately 30% of men above the age of 15 have at least one kind of genital HPV infection.
Drugs:
Aldara (imiquimod) belongs to a class of medicines known as immune response modifiers. It is indicated for the treatment of genital warts - the drug acts by stimulating the immune system to battle aberrant skin growths in patients.
SB 206 is a topical investigational drug by Novan for treating genital warts caused by HPV. This therapeutic candidate releases nitric oxide and has the potential to treat skin diseases. The Phase 2 results of SB206 12% for the treatment of external genital warts showed statistically substantial elimination of baseline warts in individuals suffering from the disease.
Ranpirnase, a ribonuclease (RNase), is a member of the enzyme superfamily that catalyzes RNA degradation and mediates a variety of important biological functions, including cell proliferation, maturation, differentiation, and cell death. It is a potential applicant for facilitating the development of medicines for life-threatening disorders like genital warts.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the genital warts market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the genital warts market
Competitive Landscape:
This report also provides a detailed analysis of the current genital warts marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the genital warts market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the genital warts market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the genital warts market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of genital warts across the seven major markets?
- What is the number of prevalent cases (2018-2034) of genital warts by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of genital warts by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with genital warts across the seven major markets?
- What is the size of the genital warts patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of genital warts?
- What will be the growth rate of patients across the seven major markets?
Genital warts: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for genital warts drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the genital warts market?
- What are the key regulatory events related to the genital warts market?
- What is the structure of clinical trial landscape by status related to the genital warts market?
- What is the structure of clinical trial landscape by phase related to the genital warts market?
- What is the structure of clinical trial landscape by route of administration related to the genital warts market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Genital Warts - Unmet Needs10 Genital Warts - Key Endpoints of Treatment13. Genital Warts - Attribute Analysis of Key Marketed and Pipeline Drugs16 Genital Warts - Recent Events and Inputs From Key Opinion Leaders18 Genital Warts Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Genital Warts - Introduction
5 Genital Warts - Disease Overview
7 Genital Warts - Epidemiology and Patient Population
8 Genital Warts - Treatment Algorithm, Guidelines, and Medical Practices
11 Genital Warts - Marketed Products
12 Genital Warts - Pipeline Drugs
14. Genital Warts - Clinical Trial Landscape
15 Genital Warts - Market Scenario
17 Genital Warts Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 813.8 Million |
| Forecasted Market Value ( USD | $ 1335.5 Million |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
